Russell House Surgery

Online: Consult your Doctor online
Telephone: 01902 842 488
Out of Hours: 111

Tirzepatide (Mounjaro®)

From today (23rd June 2025), following approval by the National Institute for Health and Care Excellence, tirzepatide (Mounjaro®) will be available through the National Health Service for eligible patients who meet the strict, nationally established criteria.

Currently, patients may be considered eligible if they have a body mass index of 40 or above, along with four or more qualifying comorbid conditions. These conditions include high blood pressure, abnormal levels of blood fats (dyslipidaemia), obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. Patients who do not meet these criteria will not be eligible for assessment during the first year of the medication’s availability.

Please do not contact your General Practitioner (GP). If you are eligible to be assessed, you will be contacted over the coming months and invited to attend an assessment appointment. Those with the highest clinical need will be prioritised for contact.

For more information about alternative local weight management services, please visit the website of the Integrated Care System for Staffordshire and Stoke on Trent (Local Weight Management Service).